{"organizations": [], "uuid": "3e05a13a3da907f83b96bbd600c6945be0c98858", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-mabvax-therapeutics-announces-posi/brief-mabvax-therapeutics-announces-positive-interim-data-from-trial-of-mvt-5873-idUSASB0C55J", "country": "US", "domain_rank": 408, "title": "BRIEF-MabVax Therapeutics Announces Positive Interim Data From Trial of MVT-5873", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-12T14:25:00.000+02:00", "replies_count": 0, "uuid": "3e05a13a3da907f83b96bbd600c6945be0c98858"}, "author": "", "url": "https://www.reuters.com/article/brief-mabvax-therapeutics-announces-posi/brief-mabvax-therapeutics-announces-positive-interim-data-from-trial-of-mvt-5873-idUSASB0C55J", "ord_in_thread": 0, "title": "BRIEF-MabVax Therapeutics Announces Positive Interim Data From Trial of MVT-5873", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-mabvax therapeutics announces positive interim data from trial", "sentiment": "negative"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "mabvax therapeutics holdings inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 26 PM / Updated 23 minutes ago BRIEF-MabVax Therapeutics Announces Positive Interim Data From Trial of MVT-5873 Reuters Staff 1 Min Read \nFeb 12 (Reuters) - MabVax Therapeutics Holdings Inc : \n* MABVAX THERAPEUTICS ANNOUNCES POSITIVE INTERIM DATA FROM EXPANDED COHORT IN PHASE 1 TRIAL EVALUATING MVT-5873 IN COMBINATION WITH FIRST-LINE CHEMOTHERAPY IN PANCREATIC CANCER \n* MABVAX THERAPEUTICS HOLDINGS - ‍MVT-5873 AT A DOSE OF 0.125 MG/KG WHEN ADDED TO FIRST-LINE CHEMOTHERAPY WAS GENERALLY WELL TOLERATED BY ALL SUBJECTS​ \n* MABVAX THERAPEUTICS HOLDINGS INC - ‍COMPANY PLANS TO ENROLL ADDITIONAL PATIENTS AT THIS DOSE TO FURTHER EXPLORE SAFETY AND POTENTIAL RESPONSE​ \n* MABVAX THERAPEUTICS HOLDINGS INC - ‍AT DOSE TESTED, ALL SIX PATIENTS IN COHORT HAD MEANINGFUL REDUCTIONS IN TUMOR VOLUME BY RECIST​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-12T14:25:00.000+02:00", "crawled": "2018-02-12T14:54:14.004+02:00", "highlightTitle": ""}